Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MYNZ
Upturn stock ratingUpturn stock rating

Mainz Biomed BV (MYNZ)

Upturn stock ratingUpturn stock rating
$1.41
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: MYNZ (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $14

1 Year Target Price $14

Analysts Price Target For last 52 week
$14Target price
Low$1.34
Current$1.41
high$22.4

Analysis of Past Performance

Type Stock
Historic Profit -30.27%
Avg. Invested days 12
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 5.26M USD
Price to earnings Ratio -
1Y Target Price 14
Price to earnings Ratio -
1Y Target Price 14
Volume (30-day avg) 2
Beta 0.3
52 Weeks Range 1.34 - 22.40
Updated Date 06/29/2025
52 Weeks Range 1.34 - 22.40
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -22.36

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -2307.21%

Management Effectiveness

Return on Assets (TTM) -80.37%
Return on Equity (TTM) -465.82%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2300208
Price to Sales(TTM) 5.89
Enterprise Value 2300208
Price to Sales(TTM) 5.89
Enterprise Value to Revenue 2.57
Enterprise Value to EBITDA -2.84
Shares Outstanding 3814850
Shares Floating 2706585
Shares Outstanding 3814850
Shares Floating 2706585
Percent Insiders 1.95
Percent Institutions 6.13

Analyst Ratings

Rating 2
Target Price 14
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Mainz Biomed BV

stock logo

Company Overview

overview logo History and Background

Mainz Biomed BV, a molecular genetics diagnostics company based in Mainz, Germany, focuses on developing and commercializing innovative, accurate, and cost-effective early detection solutions for life-threatening diseases. Founded in 2007, it has evolved from a research-focused entity to a commercial-stage company with a growing portfolio of diagnostic tests.

business area logo Core Business Areas

  • Colorectal Cancer Screening: Develops and commercializes diagnostic tests for the early detection of colorectal cancer (CRC). This includes ColoAlert, a highly sensitive and specific stool DNA test.
  • Gastrointestinal Disease Diagnostics: Expands its portfolio to include tests for other gastrointestinal diseases to enhance diagnostic capabilities and patient care.

leadership logo Leadership and Structure

The leadership team consists of experienced professionals in the fields of molecular diagnostics, biotechnology, and business development. The company's organizational structure includes departments dedicated to research and development, clinical affairs, regulatory affairs, commercial operations, and finance.

Top Products and Market Share

overview logo Key Offerings

  • ColoAlert: ColoAlert is a non-invasive stool DNA test for the early detection of colorectal cancer. It detects tumor DNA and is designed to be more convenient for patients than traditional colonoscopies. Market share is still emerging. Competitors include Exact Sciences' Cologuard (EXAS), and various fecal immunochemical tests (FIT). No current market share data available.
  • PancarAlert: An early detection test for pancreatic cancer, which is in development. No current market share data available as it is not commercially available. Competitors would include imaging technologies and liquid biopsies.

Market Dynamics

industry overview logo Industry Overview

The molecular diagnostics market for cancer screening is growing due to increasing awareness of early detection benefits, technological advancements, and an aging population. The market is competitive, with established players and emerging companies vying for market share.

Positioning

Mainz Biomed BV is positioning itself as a leader in convenient and accurate early detection of CRC with ColoAlert. Its competitive advantage lies in its proprietary technology and commitment to patient-friendly diagnostic solutions.

Total Addressable Market (TAM)

The TAM for colorectal cancer screening is estimated to be in the billions of dollars globally. Mainz Biomed BV is aiming to capture a significant share of this market through the increased adoption of its ColoAlert test.

Upturn SWOT Analysis

Strengths

  • Proprietary technology platform
  • Non-invasive and patient-friendly tests
  • Focus on early cancer detection
  • Experienced leadership team
  • Regulatory approvals in key markets

Weaknesses

  • Limited commercial infrastructure compared to larger competitors
  • Dependence on successful commercialization of ColoAlert
  • Need for ongoing clinical validation of tests
  • Relatively small market cap

Opportunities

  • Expanding market for non-invasive cancer screening
  • Potential partnerships with healthcare providers and insurance companies
  • Geographic expansion into new markets
  • Development of new diagnostic tests for other diseases
  • Increasing awareness and acceptance of stool DNA testing

Threats

  • Competition from established players with greater resources
  • Changes in regulatory landscape
  • Adverse clinical trial results
  • Pricing pressures from insurance companies and healthcare providers
  • Slow adoption of new diagnostic technologies

Competitors and Market Share

competitor logo Key Competitors

  • EXAS

Competitive Landscape

Mainz Biomed BV faces competition from established players such as Exact Sciences (EXAS) and other companies offering colonoscopy services and FIT tests. Mainz Biomed BV's competitive advantage lies in the non-invasive nature and convenience of its ColoAlert test, as well as its focus on early cancer detection. It needs to scale quickly to capture market share.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is driven by regulatory approvals, partnerships, and initial commercial traction for ColoAlert.

Future Projections: Future growth is projected to be significant, driven by increasing adoption of ColoAlert and the potential development and commercialization of PancarAlert. Analyst estimates vary but generally reflect optimism about the company's potential.

Recent Initiatives: Recent initiatives include expanding commercial operations in Europe, pursuing FDA approval for ColoAlert in the United States, and advancing the development of PancarAlert.

Summary

Mainz Biomed BV is an emerging growth company focused on early cancer detection. Its ColoAlert test is a promising non-invasive alternative to traditional colonoscopies. The company needs to scale its commercial operations and secure regulatory approvals to achieve its growth potential. It faces competition from larger, established players, and success depends on the wide adoption of its tests.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Mainz Biomed BV's Investor Relations
  • SEC Filings
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and a thorough understanding of the company's financials and prospects.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Mainz Biomed BV

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-11-05
CEO & Executive Director Mr. Guido Baechler
Sector Healthcare
Industry Diagnostics & Research
Full time employees 19
Full time employees 19

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.